Sinovac Biotech, Ltd.: shareholders and insiders

SVANASDAQHealthcare · Pharmaceutical Preparations

Price

$6.47

November 17, 2026Market cap $465M

What Ploutos Investor adds for Sinovac Biotech

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • A figure that did not match the numbers it is built from has been left out.

Insiders and their shares

Purchases and sales by officers and directors, from their own Form 4 filings.

Sorry, we do not have enough data

for purchases and sales by Sinovac Biotech's insiders

Why?

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

5 Holders over 5%5 On a 13DDec 17, 2025 Latest filing
  • 1Globe Capital LLCwith 2 more personsCommon Shares, par value $0.001 per share
    Share of class32.3%
  • SAIF Partners IV L.P.with 2 more personsCommon Shares, par value US$0.001 per share
    Share of class15.0%
  • Weidong YinCommon Shares
    Share of class8.85%
  • Advantech Capital L.P.with 3 more personsCommon Shares
    Share of class8.14%
  • Vivo Capital VIII, LLCwith 1 more personCommon Shares, $0.001 par value per share
    Share of class6.30%

What the holders on a 13D state as their purpose

From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.

  • 1Globe Capital LLC32.3%From the filing of Sep 12, 2025

    Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On July 25, 2025, Vivo Capital Surplus Fund VIII, L.P. ("Vivo Fund VIII") filed an amended complaint (the "Amended Complaint") with the U.S. District Court for the Commonwealth of Massachusetts in the civil action initiated by Vivo Fund VIII on April 14, 2025 and previously disclosed in Amendment No. 6 to the Schedule 13D (the "Vivo Action"). In the Amended Complaint, Vivo Fund VIII alleges a disclosure violation claim under Section 13(d) of the Securities Exchange Act of 1934, repeating in a single count the allegations that appeared in its original complaint. Among other things, Vivo Fund VIII alleges that (1) Dr.…

    From the filing of Sep 12, 2025
  • SAIF Partners IV L.P.15.0%From the filing of Jul 14, 2025

    Item 4 is hereby amended and supplemented to add the following: The Issuer disclosed on July 10, 2025 a new board of directors of the Issuer (the "Board") comprising Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y Yan (as Chairman of the Board) and Mr. Yin Weidong. The Reporting Persons have also engaged and will continue to engage in discussions with other shareholders of the Issuer regarding the Board, the corporate governance of the Issuer and similar matters that the Reporting Persons believe would increase shareholder value, as well as pursue other plans or proposals that relate to or would…

    From the filing of Jul 14, 2025
  • Weidong Yin8.9%From the filing of Jul 15, 2025

    Item 4 is hereby amended and supplemented to add the following: The Issuer announced on July 10, 2025 a new board of directors of the Issuer (the "Board"), comprising Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y Yan (as Chairman of the Board) and the Reporting Person. The Reporting Person has accepted the appointment and plans to participate in the future governance of the Issuer as a member of the newly Board. Except as set forth in this Item 4, the Reporting Person has no present plan or intention that would resu lt in or relate to the listed transactions described in Item 4 of Schedule 13D.…

    From the filing of Jul 15, 2025
  • Advantech Capital L.P.8.1%From the filing of Jul 14, 2025

    Item 4 is hereby supplemented and amended by adding the following: On July 7, 2025, the High Court of Antigua and Barbuda granted an interim injunction prohibiting the Reporting Persons and certain other shareholders from voting their shares at the Special Meeting (the "Injunction Order"). On July 8, 2025, the Court of Appeal of the Eastern Caribbean Supreme Court issued an order staying the Injunction Order (the "Stay Order"). After the Court of Appeal issued the Stay Order, the Special Meeting of Shareholders of the Issuer requisitioned by SAIF Partners IV L.P. ("SAIF") (the "Special Meeting") was convened. Mr. Chiang Li delivered a short statement and then purported to adjourn the…

    From the filing of Jul 14, 2025
  • Vivo Capital VIII, LLC6.3%From the filing of Jul 11, 2025

    Item 4 is hereby supplemented and amended by adding the following: On May 19, 2025, the Issuer gave notice of a Special Meeting of Shareholders to be held on July 8, 2025 and announced an intention to exclude shares held by the Reporting Persons and another investor from the vote. On May 30, 2025, the Issuer filed an application for an injunction in the High Court of Antigua and Barbuda seeking an order prohibiting the Reporting Persons and the other investor from voting their shares at the Special Meeting. The Reporting Persons have opposed such an injunction in the High Court and the Court of Appeal of the Eastern Caribbean Supreme Court, and, on July 8, 2025, the Court of Appeal issued…

    From the filing of Jul 11, 2025

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Renaissance Technologies
    In the quarter

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 0.11% of its shares outstanding were held short, +0.0% since the report before.

Shares held short
82.2K
0.11%
Since the report before82.2K on Sep 30, 2026
+0.0%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 138.0K
  • Nov 15, 2023: Shares held short 138.0K
  • Nov 30, 2023: Shares held short 138.0K
  • Dec 15, 2023: Shares held short 138.2K
  • Dec 29, 2023: Shares held short 138.0K
  • Jan 12, 2024: Shares held short 138.0K
  • Jan 31, 2024: Shares held short 138.0K
  • Feb 15, 2024: Shares held short 138.0K
  • Feb 29, 2024: Shares held short 138.0K
  • Mar 15, 2024: Shares held short 133.3K
  • Mar 28, 2024: Shares held short 130.8K
  • Apr 15, 2024: Shares held short 130.8K
  • Apr 30, 2024: Shares held short 82.8K
  • May 15, 2024: Shares held short 82.8K
  • May 31, 2024: Shares held short 82.8K
  • Jun 14, 2024: Shares held short 82.8K
  • Jun 28, 2024: Shares held short 82.8K
  • Jul 15, 2024: Shares held short 82.8K
  • Jul 31, 2024: Shares held short 82.8K
  • Aug 15, 2024: Shares held short 82.8K
  • Aug 30, 2024: Shares held short 82.2K
  • Sep 13, 2024: Shares held short 82.2K
  • Sep 30, 2024: Shares held short 82.2K
  • Oct 15, 2024: Shares held short 82.2K
  • Oct 31, 2024: Shares held short 81.7K
  • Nov 15, 2024: Shares held short 81.7K
  • Nov 29, 2024: Shares held short 81.7K
  • Dec 13, 2024: Shares held short 81.7K
  • Dec 31, 2024: Shares held short 81.8K
  • Jan 15, 2025: Shares held short 81.8K
  • Jan 31, 2025: Shares held short 81.8K
  • Feb 14, 2025: Shares held short 81.8K
  • Feb 28, 2025: Shares held short 81.8K
  • Mar 14, 2025: Shares held short 81.8K
  • Mar 31, 2025: Shares held short 81.8K
  • Apr 15, 2025: Shares held short 81.8K
  • Apr 30, 2025: Shares held short 81.8K
  • May 15, 2025: Shares held short 81.8K
  • May 30, 2025: Shares held short 81.8K
  • Jun 13, 2025: Shares held short 81.8K
  • Jun 30, 2025: Shares held short 81.8K
  • Jul 15, 2025: Shares held short 81.8K
  • Jul 31, 2025: Shares held short 83.0K
  • Aug 15, 2025: Shares held short 83.0K
  • Aug 29, 2025: Shares held short 83.0K
  • Sep 15, 2025: Shares held short 83.0K
  • Sep 30, 2025: Shares held short 83.0K
  • Oct 15, 2025: Shares held short 82.7K
  • Oct 31, 2025: Shares held short 82.7K
  • Nov 14, 2025: Shares held short 82.7K
  • Nov 28, 2025: Shares held short 82.7K
  • Dec 15, 2025: Shares held short 82.8K
  • Dec 31, 2025: Shares held short 82.8K
  • Jan 15, 2026: Shares held short 82.8K
  • Jan 30, 2026: Shares held short 82.8K
  • Feb 13, 2026: Shares held short 82.8K
  • Feb 27, 2026: Shares held short 82.8K
  • Mar 13, 2026: Shares held short 82.8K
  • Mar 31, 2026: Shares held short 82.8K
  • Apr 15, 2026: Shares held short 82.8K
  • Apr 30, 2026: Shares held short 82.8K
  • May 15, 2026: Shares held short 82.7K
  • May 29, 2026: Shares held short 82.7K
  • Jun 15, 2026: Shares held short 82.2K
  • Jun 30, 2026: Shares held short 82.2K
  • Jul 15, 2026: Shares held short 82.2K
  • Jul 31, 2026: Shares held short 82.2K
  • Aug 14, 2026: Shares held short 82.2K
  • Aug 31, 2026: Shares held short 82.2K
  • Sep 15, 2026: Shares held short 82.2K
  • Sep 30, 2026: Shares held short 82.2K
  • Oct 15, 2026: Shares held short 82.2K

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

29 Managers, Q2 2026$225M Value of their positions
  • Q3 2025: Managers 27
  • Q4 2025: Managers 28
  • Q1 2026: Managers 28
  • Q2 2026: Managers 29

Institutional investors by quarter

The fund managers holding SVA, quarter by quarter, from Q2 2013 to Q2 2025, 49 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 29 managers held 10.47M shares, worth $225M. During the quarter 4 opened a position, 3 closed one, 2 added and 5 trimmed.

The largest holders, Q2 2026

  • Vivo Capital
    In the quarter
  • Orbimed Advisors
    In the quarter
  • Renaissance Technologies
    In the quarter
  • Neumann Advisory Hong Kong
    In the quarter
  • California Public Employees Retirement System
    In the quarter
  • Skandinaviska Enskilda Banken AB (publ)
    In the quarter-50%
  • Spark Investment Management
    In the quarter
  • Geode Capital Management
    In the quarter
  • Susquehanna International Group
    In the quarter
  • Navellier & Associates
    In the quarter

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Sinovac Biotech's filings show?

Who buys and sells is one part of Sinovac Biotech's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about SVA's shareholders

Didn't find what you were looking for?

Ask us
Have SVA's insiders bought or sold?

From – to – Sinovac Biotech's insiders reported no purchase or sale of shares on the market.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.